The markets opened higher with the Dow rising 34 points to 18,070 as producer prices held steady in August. Nasdaq gained 20 points to 5,194.
On the upside
Aerie Pharmaceuticals (Nasdaq: AERI) reported positive primary efficacy results from a Phase 3 "Mecury 1" clinical trial of Roclatan.
South Florida Business Journal named Net Element (Nasdaq: NETE) to its Top 25 Fastert-Growing Technology Companies.
AcelRx Pharmaceuticals (Nasdaq: ACRX) reported positive results from a Phase 3 study of ARX-04 to treat moderate to severe acute pain in post-operative study patients.
On the downside
Investors locked in profits on Acasti Pharma (Nasdaq: ACST).
Platform Specialty Products (NYSE: PAH) commenced an offering of $350 million of its common stock.
Profit taking weighed down shares of Sarepta Therapeutics (Nasdaq: SRPT).
In the broad market, advancing issues outpaced decliners by a margin of nearly 5 to 4 on the NYSE and by more than 9 to 7 on Nasdaq. The broader S&P 500 rose 3 points to 2,129. Bitcoin eased a fraction to $608.
